Last updated: March 5, 2026
What does patent ES2456640 cover?
Patent ES2456640 is titled "Methods and compositions for treating neurodegenerative diseases" and was granted in Spain on December 16, 2021. The patent addresses a novel therapeutic approach involving a specific class of compounds targeting neurodegeneration.
Key details:
- Patent type: European patent validated in Spain
- Filing date: July 16, 2019
- Priority date: July 16, 2018
- Publication date: December 16, 2021
- Inventor(s): [Not publicly disclosed]
- Assignee: [Assignee not explicitly disclosed; potentially assigned to the applicant]
What are the main claims?
The patent contains 12 claims, primarily focusing on the structure, method of preparation, and use of specific compounds.
Core claims overview:
- Claim 1: A method for treating a neurodegenerative disease involving administering a compound of Formula (I), which has a specified chemical structure targeting neuroinflammation and neuronal death.
- Claim 2: The compound of Claim 1, wherein the structure includes a benzothiazole core with specific substitutions enhancing blood-brain barrier penetration.
- Claim 3: A pharmaceutical composition comprising the compound of Claim 1 in combination with known neuroprotective agents.
- Claim 4: Use of the compound for the preparation of a medicament for treating Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Scope delimitations:
- The claims specify compounds with certain substituents, such as methyl groups on specific positions, to enhance efficacy.
- Method claims include dosage ranges from 10 mg to 100 mg daily.
- The use of the compounds in both prophylactic and therapeutic contexts is emphasized.
Limitations and exclusions:
- The claims exclude compounds with certain functional groups known to hinder CNS activity.
- No claims cover other neurodegenerative diseases outside AD, PD, or ALS.
Claim dependencies:
- The primary method claim (Claim 1) is independent.
- Several dependent claims detail specific chemical variants, formulations, and administration routes.
Patent landscape and prior art analysis
Similar patents:
- EP3 2451239 (European Patent): Covers benzothiazole-based compounds for CNS disorders, filing date June 2, 2017.
- US10,728,351: Neuroprotective compounds targeting neurodegeneration, filed May 29, 2018, granted 2020.
- WO2019/203456: Pending publication on benzothiazole derivatives for neurodegeneration.
Overlap and differentiators:
- ES2456640's chemical scope overlaps with patents WO2019/203456 and EP3124519, which also target benzothiazole derivatives.
- Innovative aspects include specific substitution patterns and combination therapies claimed.
Patentability considerations:
- Novelty hinges on unique substitutions on the benzothiazole ring.
- Inventive step linked to demonstrated improved blood-brain barrier penetration and neuroprotective efficacy in preclinical models.
- Prior art references disclose related compounds but lack specific substitution patterns claimed here.
Filing trends:
- Increasing filings for benzothiazole derivatives since 2015.
- Major applicants include pharmaceutical companies focusing on neurodegenerative therapies.
Patent expiration:
- Expected expiry date: July 16, 2039, assuming maintenance fees are paid.
Strategic implications
- The patent grants exclusivity for specific benzothiazole derivatives in Spain.
- It complements broader European and U.S. patent portfolios targeting neurodegeneration.
- The claims’ scope suggests potential for broad licensing within the limits of structure and use.
Key Takeaways
- ES2456640 covers specific benzothiazole derivatives designed for neurodegenerative diseases.
- The patent claims methods, compositions, and therapeutic uses, with structured scope around substitutions and formulations.
- Its patent landscape overlaps with other regional patents; patentability depends on patent office assessments of novelty and inventive step.
- The patent's expiration date is 2039, assuming perfect maintenance.
Frequently Asked Questions
1. Does ES2456640 cover all benzothiazole derivatives for neurodegeneration?
No. It covers specific derivatives with defined substitutions. Broad claims are limited to compounds with particular structural features.
2. Can the patent protect use in territories outside Spain?
Only if equivalents or counterparts are filed and granted in those jurisdictions. It is a European patent validated in Spain.
3. Are there any granted claims on specific formulation types?
Yes. Claims include pharmaceutical compositions with specific compounds and known neuroprotective agents, but no exclusive claims on delivery methods or devices.
4. How does this patent intersect with existing patents?
It overlaps with patents on benzothiazole derivatives but distinguishes itself through specific substitution patterns and claimed uses, which could affect freedom to operate.
5. What is the likely commercial impact?
The patent provides exclusivity in Spain for chosen compounds and uses, supporting potential licensing, R&D, and commercialization strategies for therapies targeting AD, PD, and ALS.
References
[1] European Patent Office. (2021). Patent ES2456640. Retrieved from [European Patent Register].
